SCHEMBL9529930

SCHEMBL9529930

N#Cc1ccc(NC(=S)NCc2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.71
MAOA P21397 1/20 0.71
MAPT P10636 4/20 0.66
NPSR1 Q6W5P4 1/20 0.66
SMN1; SMN2 Q16637 3/20 0.64
POLB P06746 2/20 0.64
RAB9A P51151 2/20 0.64
MEN1 O00255 6/20 0.62
KMT2A Q03164 6/20 0.62
GAA P10253 4/20 0.62
ALDH1A1 P00352 4/20 0.61
NPC1 O15118 1/20 0.58
HPGD P15428 2/20 0.58
LSS P48449 1/20 0.58
ALOX12 P18054 2/20 0.57
CA9 Q16790 1/20 0.57
ATM Q13315 1/20 0.57
LMNA P02545 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8612547 0.87 MAOB (0.92) MAOBMAOAMAPTNPSR1SMN1; SMN2
SCHEMBL11647542 0.85 ALDH1A1 (0.68) MAPTSMN1; SMN2KMT2AALDH1A1LSS
SCHEMBL9529391 0.85 RAB9A (0.72) MAOBMAOAMAPTSMN1; SMN2RAB9A
SCHEMBL18695068 0.84 ALDH1A1 (0.71) MAOBMAOAMAPTNPSR1POLB
SCHEMBL11649434 0.84 POLB (0.70) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL1520659 0.84 MAOB (1.00) MAOBMAOAMAPTNPSR1SMN1; SMN2
SCHEMBL8612629 0.82 MAOB (0.83) MAOBMAOAMAPTNPSR1SMN1; SMN2
SCHEMBL6295850 0.82 ALDH1A1 (0.72) MAOBMAOAMAPTRAB9AMEN1
SCHEMBL18737741 0.82 MEN1 (0.46) MAOBMAOAMAPTNPSR1SMN1; SMN2
SCHEMBL18695146 0.82 NAMPT (0.64) MAOBMAPTSMN1; SMN2POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9907766-B2 Sweetness receptor antagonist AJINOMOTO CO., INC. (JP) 2018-03-06 US disclosed
US-9907766-B2 Sweetness receptor antagonist AJINOMOTO CO., INC. (JP) 2018-03-06 US disclosed
US-9907766-B2 Sweetness receptor antagonist AJINOMOTO CO., INC. (JP) 2018-03-06 US disclosed
EP-3162366-A1 SWEETNESS RECEPTOR ANTAGONIST Ajinomoto Co., Inc. (JP) 2017-05-03 EP disclosed
US-20170101372-A1 SWEETNESS RECEPTOR ANTAGONIST AJINOMOTO CO., INC. (JP) 2017-04-13 US disclosed
US-20170101372-A1 SWEETNESS RECEPTOR ANTAGONIST AJINOMOTO CO., INC. (JP) 2017-04-13 US disclosed
US-20170101372-A1 SWEETNESS RECEPTOR ANTAGONIST AJINOMOTO CO., INC. (JP) 2017-04-13 US disclosed
EP-0299533-B1 HIGH POTENCY SWEETENING AGENTS THE NUTRASWEET COMPANY (a Delaware corporation) (US) 1993-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170101372-A1 SWEETNESS RECEPTOR ANTAGONIST GPR119, GLP1R, SUCNR1 MAOB 4217/4885MAOA 4407/4885MAPT 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.